New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
09:16 EDTITW, RVNC, XRX, GSK, PLXT, BEBE, MCD, LXK, ALSN, FB, HOG, CMCSA, AGN, NVS, NFLX, FEYE, VRXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Netflix (NFLX), up 8%... Harley-Davidson (HOG), up 7%... PLX Technology (PLXT), up 8%... Illinois Tool (ITW), up 2.3%... Comcast (CMCSA), up 1%... McDonald's (MCD), up 0.6%. ALSO HIGHER: Allergan (AGN), up 17% after Valeant (VRX) confirms proposal to combine with the company for $48.30 and 0.83 shares of stock. Valeant is up 5% following its confirmation of the news that broke last night... GlaxoSmithKline (GSK), up 4.5% after agreeing to sell oncology products for $14.5B to Novartis (NVS) and buy Novartis' Vaccines business, currently excluding its flu business, for $7.1B plus royalties. Novartis shares trading in New York are also up 1% following the deals... Revance Therapeutics (RVNC), up 20% after announcing positive results from RT002 Phase 1/2 study... Facebook (FB), up 2% following upgrade at Credit Suisse. DOWN AFTER EARNINGS: Xerox (XRX), down 4%... Lexmark (LXK), down 4.8%. ALSO LOWER: Allison Transmission (ALSN), down 4% after filing to sell 25M shares for holders... FireEye (FEYE), down 2.9% after filing to sell 13.3M shares of common stock for holders... Bebe stores (BEBE), down 16% after reporting preliminary Q3 losses that were steeper than the consensus estimate.
News For AGN;VRX;NFLX;CMCSA;FEYE;NVS;GSK;HOG;MCD;XRX;FB;BEBE;RVNC;ALSN;PLXT;ITW;LXK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
December 8, 2014
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
12:40 EDTMCDOn The Fly: Midday Wrap
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:29 EDTNFLXNetflix falls to session lows, levels to watch
The shares are down over 2% to $342.44. At that price next support is at $340.05. Resistance is at $345.45.
10:08 EDTMCDMcDonald's falls on weak November sales, levels to watch
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTITWOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
09:54 EDTFEYEFireEye calls active on renewed takeover chatter
FireEye December 31 and January 33 calls are active on 6300 contracts (800 puts) on renewed takeover chatter. December weekly call option implied volatility is at 67, December is at 53 compared to its 26-week average of 57 according to Track Data. Active call volume suggests traders taking positions for upside price movement.
09:48 EDTMCDMarket begins lower, averages turns mixed in early trade
Stock futures trade below fair value throughout the pre-market trading session, leading to a lower open for the broader market. The Dow finished last week at an all-time high and just slightly below its next milestone level of 18,000, but it continues to be weighed on during early trading from McDonald's (MCD), which is down over 3% following its November sales report. In early trading, the Dow is down 17 points, the Nasdaq is up 7 points and the S&P is down 1 point.
09:40 EDTFEYERumor: FireEye moves up on renewed takeover chatter
Subscribe for More Information
09:38 EDTMCDMcDonald's sees Q4 margins 'significantly pressured' by top-line performance
Subscribe for More Information
09:20 EDTMCDOn The Fly: Pre-market Movers
Subscribe for More Information
07:59 EDTMCDMcDonald's reports November global comparable sales decreased 2.2%
Subscribe for More Information
07:56 EDTITWIllinois Tool Works price target raised to $110 from $95 at Stifel
Subscribe for More Information
07:29 EDTAGNUBS to hold investor trip
Subscribe for More Information
07:28 EDTFEYEFBN Securities to hold a bus tour
Subscribe for More Information
07:18 EDTAGNUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
07:07 EDTITWIllinois Tool Works upgraded to Buy from Accumulate at Global Hunter
Global Hunter upgraded Illinois Tool Works to Buy based on strong 2015 guidance, shareholder returns, and operating leverage. Price target raised to $111 from $92.
06:42 EDTMCDMcDonald's coverage resumed with a Neutral at Goldman
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use